Retina Clinical Trials

None

None

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to investigate: how will pseudophakic patients respond in terms of objective and subjective outcomes, when treated with Dextenza compared to topical prednisolone acetate following gas bubble repair and laser for RD.

Combined Laser-surgical Technology of RRD Treatment

Purpose: to assess the efficacy and safety of combined laser-surgical technology of RRD treatment

Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics

Subjects undergo vitreous substitution with either SF6 gas or fluid during vitrectomy.

Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities

This tool can be used to measure a therapeutic benefit for new treatments (like gene therapy, retinal implants, intra vitreous injections ) for visual loss patients.

Baseline Relative Peripheral Refraction in Myopia Control

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses impose myopic defocus in the central or peripheral retina, with myopia progression being retarded by 50% to 60%. However, the optimal amount of myopic defocus has not yet been determined.

Group Activities to Support Addiction Recovery

Exclusion criteria form the Arm A HB group and the Arm B group include having been diagnosed with a bipolar disorder or a psychotic disorder or having had psychotic symptoms at any point in life, diagnosed with a cardiac condition, received care for a cardiac condition, or have current cardiac …

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active residual or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.